mouse Anti-Epilepsy, Progressive Myoclonus Type 2A (Lafora Disease, EPM2A, Laforin, LD, LDE, EPM2, MELF, LAFPTPase, FLJ11207, KIAA0766) Monoclonal Antibody [Clone:9H116]

Laforin, also known as Lafora PTPase and EPM2A, is a 38kD member of the protein tyrosine phosphatase family. Human Laforin is 331 aa in length and contains one carbohydrate binding type-20 (CBM20) domain (aa 1-124) and one tyrosine-protein phosphatase domain (aa 243-311). Multiple splicing variants produce four isoforms of human Laforin, which is most highly expressed in heart, skeletal muscle, kidney, pancreas and brain. It functions as a dual specificity protein phosphatase and may be involved in the control of glycogen metabolism. Mutations in Laforin cause progressive myoclonic epilepsy type 2, also known as Lafora disease.

Applications:
Suitable for use in Western Blot. Other applications not tested.

Recommended Dilution:
Western Blot: 1ug/ml
Optimal dilutions to be determined by the researcher.

Storage and Stability:
Lyophilized and reconstituted products are stable for 12 months after receipt at -20°C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.